Oragenics, Inc. OGEN 深 滬
等待開盤 04-28 09:30:00 美东时间
0.637
-0.005
-0.78%
華盛通- 最 高0.6625
- 今 開0.6507
- 成交量 1.51万股
- 最 低 0.637
- 昨 收 0.642
- 總市值 276.21万
- 52周最高 7.60
- 市盈率 靜 --
- 換手率 0.35%
- 52周最低 0.5038
- 委 比 -80.65%
- 總股本 433.60万
- 歷史最高 83700.00
- 量 比 0.62
- 振 幅 3.97%
- 歷史最低 0.5038
- 每 手 1
- 風險率 1.58%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Oragenics Says 2 Patients And 8 Study Drug Doses Administered In Ongoing Phase Iia Clinical Trial Evaluating ONP-002, Lead Candidate For Treatment Of Mild Traumatic Brain Injury
• Enrollment underway at Mackay Base Hospital in Queensland, Australia; additional sites in final activation stagesSARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage
04-20 21:04
Oragenics Doses First Patient In Phase IIa Clinical Trial of ONP-002
Mackay Base Hospital activated March 31, 2026 as first clinical trial site; first patient dosed within days of activation — a signal of strong enrollment velocity and significant unmet medical need
04-13 20:34
Oragenics Sets New 2025 Annual Shareholder Meeting Date
The latest update is out from Oragenics ( ($OGEN) ). On March 27, 2026, Orageni...
04-01 07:45
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
Oragenics, Inc. announced that its audited consolidated financial statements for the year ended December 31, 2025, include an unqualified audit opinion with a going concern explanatory paragraph. The Annual Report on Form 10-K, filed on March 16, 2026, is available on the SEC's EDGAR system and the company's investor relations website. The company specializes in brain-targeted therapeutics via proprietary intranasal delivery technology, focusing ...
03-25 22:30
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K
Oragenics, Inc. reported significant progress in 2025, transitioning to a focused biotech company with key milestones including NYSE compliance, clinical trial advancements, manufacturing shift to the U.S., and AI partnerships. The company raised $16.5 million, repaid debt, and reduced expenses. In early 2026, they secured ethics approval, initiated trial sites, and prepared for U.S. clinical activities. Priorities for 2026 include completing Pha...
03-17 12:30
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION
Oragenics, Inc. has completed the first site initiation visit (SIV) for its Phase IIa clinical trial of ONP-002 in Australia. The trial aims to evaluate the safety and efficacy of ONP-002, a first-in-class intranasal neurosteroid, in patients with acute concussion and mild traumatic brain injury (mTBI). The first of three planned trial sites is fully operational, with the remaining two sites expected to complete their final regulatory reviews soo...
03-12 12:30
Oragenics Receives Approval From Australia's Human Research Ethics Committee To Start Phase IIa Clinical Study Of ONP-002 For Concussion Treatment
Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that it has received final Human
03-10 20:33
Oragenics receives Australia HREC approval to start ONP-002 Phase IIa concussion trial
Oragenics receives Australia HREC approval to start ONP-002 Phase IIa concussion trial Oragenics said it received final Human Research Ethics Committee (HREC) approval in Australia to begin a Phase IIa trial of ONP-002 for concussion and mild traumatic brain injury. The company said all required reg
03-10 20:30
Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia
Oragenics, Inc. has received final Human Research Ethics Committee (HREC) approval in Australia to commence its Phase IIa clinical trial for ONP-002, a potential first-in-class pharmacological treatment for mild traumatic brain injury (mTBI). The trial will enroll 40 patients across three Australian sites, with dosing expected to begin by March 2026. ONP-002 targets the underlying biology of mTBI, aiming to reduce neuroinflammation and oxidative ...
03-10 12:30
Oragenics Previews 2026 Milestones; Outlines Clinical And Growth Catalysts For ONP-002 In Concussion And mTBI
Oragenics, Inc. (NYSE:OGEN) ("the "Company") a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today previewed its targeted milestones for
02-09 21:38
